Dermapharm Holding SE

BRIEF

published on 03/10/2026 at 09:16, 11 days 6 hours ago

Dermapharm Holding SE Announces Share Buyback Offer

Share Buyback Dermapharm Holding SE Capital Measures 4,300,000 Shares EUR 42.00 Per Share
PRESS RELEASE

published on 03/10/2026 at 09:11, 11 days 6 hours ago

EQS-Adhoc: Dermapharm Holding SE resolves public share buyback offer for up to 4,300,000 shares
Dermapharm Holding SE resolves public share buyback offer for up to 4,300,000 shares, at EUR 42.00 per share. Details at https://ir.dermapharm.de

Investor Relations Share Buyback Offer Public Offer Dermapharm Holding SE EUR 42.00 Per Share
BRIEF

published on 03/10/2026 at 07:35, 11 days 8 hours ago

Dermapharm Reports Revenue Decline, EBITDA Improvement in 2025

Revenue Decline EBITDA Growth Healthcare Products Dermapharm 2025 Earnings
PRESS RELEASE

published on 03/10/2026 at 07:30, 11 days 8 hours ago

Dermapharm Holding SE records decline in consolidated revenue, adjusted consolidated EBITDA improves
Dermapharm Holding SE reports decline in consolidated revenue for 2025 but shows improved adjusted consolidated EBITDA margins. Company's earnings and margins heavily impacted by structural measures

Adjusted EBITDA Pharmaceuticals Consolidated Revenue Annual Results Dermapharm Holding SE
BRIEF

published on 11/13/2025 at 07:35, 4 months 8 days ago

Dermapharm Maintains Stability Amid Portfolio Adjustments

Growth And Earnings Branded Pharmaceuticals Dermapharm 2025 Financial Results Portfolio Restructuring
PRESS RELEASE

published on 11/13/2025 at 07:30, 4 months 8 days ago

Stable earnings despite portfolio adjustment - 2025 guidance confirmed, strong growth in branded pharmaceuticals
Dermapharm Holding SE reports stable earnings despite portfolio adjustments in Q3 2025, confirms 2025 guidance and strong growth in branded pharmaceuticals

Pharmaceuticals Growth Earnings Dermapharm Holding SE Portfolio Adjustment
BRIEF

published on 08/26/2025 at 07:35, 6 months 26 days ago

Dermapharm Reports Stable Business in H1 2025 and Q2 EBITDA Growth

Financial Results EBITDA Growth Revenue Stability Branded Pharmaceuticals Dermapharm Performance
PRESS RELEASE

published on 08/26/2025 at 07:30, 6 months 26 days ago

Dermapharm confirms stable business development in H1 2025 and records EBITDA growth in Q2 versus prior-year quarter
Dermapharm confirms stable business development in H1 2025 with EBITDA growth in Q2. Full-year guidance for 2025 reiterated. Branded pharmaceuticals main growth driver

Revenue Pharmaceuticals EBITDA Growth Dermapharm H1 2025
BRIEF

published on 08/12/2025 at 07:35, 7 months 9 days ago

Dermapharm Holding SE Continues Growth in Q2 2025

Revenue Forecast EBITDA Growth Branded Pharmaceuticals Dermapharm Q2 2025 Performance
PRESS RELEASE

published on 08/12/2025 at 07:30, 7 months 9 days ago

Dermapharm Holding SE remains on projected growth trajectory in Q2 2025
Dermapharm Holding SE reports Q2 2025 results in line with expectations. Confirms full-year guidance of EUR 1,160–1,200 million revenue and EUR 322–332 million EBITDA

Pharmaceuticals EBITDA Growth Dermapharm Holding SE Full-year Guidance Q2 2025 Results

1 2 ... 5

Published on 03/20/2026 at 23:00, 17 hours 10 minutes ago

Cypher Announces Private Placement
Published on 03/20/2026 at 21:30, 18 hours 40 minutes ago

Sky Gold Sets Options
Published on 03/20/2026 at 21:15, 18 hours 55 minutes ago

Earthwise Minerals Announces Private Placement
Published on 03/20/2026 at 13:30, 1 day 2 hours ago

Unusual Machines Announces Pricing of Approximately $150 Million Public Offering of Common Stock
Published on 03/20/2026 at 12:30, 1 day 3 hours ago

CANEX Metals Announces the Numbers of Gold Basin Shares Taken up by Canex Metals

View all ACCESSWIRE

Published on 03/20/2026 at 22:45, 17 hours 24 minutes ago

Investor Alert: Berger Montague (Canada) PC represents investors that purchased shares of Super Micro Computer, Inc. listed on the CBOE Canada and elsewhere
Published on 03/20/2026 at 21:05, 19 hours 4 minutes ago

Fractal EMS Receives ISO/IEC 9001 and 27001 Certifications
Published on 03/20/2026 at 21:05, 19 hours 5 minutes ago

Nebius Group announces closing of private offering of convertible senior notes, with aggregate gross proceeds of approximately $4.3 billion
Published on 03/20/2026 at 21:00, 19 hours 9 minutes ago

BRP Unveils the Winners of its 6th International Design Challenge
Published on 03/20/2026 at 20:05, 20 hours 4 minutes ago

INVESTOR ALERT: Goeasy Ltd. Shareholder Class Action

View all EQS

Published on 03/20/2026 at 19:00, 21 hours 10 minutes ago

AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 18:15, 21 hours 55 minutes ago

Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 17:45, 22 hours 25 minutes ago

Cie du Bois Sauvage : Annual report 2025
Published on 03/20/2026 at 16:57, 23 hours 12 minutes ago

Number of shares and voting rights - February 2026 (In French only)
Published on 03/19/2026 at 18:00, 1 day 22 hours ago

Filing of the 2025 Universal Registration Document

View all LES ECHOS COMFI WIRE

News